하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
HIRONIC marked the 20th anniversary of its founding on July 12, 2026. The company was established in 2006 as SP Medical, a name derived from "Success Partner," and has since grown into a KOSDAQ-listed developer and manufacturer of medical aesthetic devices with a presence in more than 60 countries.
Two Decades of Development
HIRONIC's founding period (2006–2010) centered on the development of its first medical devices and the establishment of its early patent portfolio. Between 2011 and 2016, the company listed on KOSDAQ and introduced the DOUBLO line of devices, a technology platform later upheld through a defended patent ruling.
From 2017 to 2020, HIRONIC received FDA and CE approvals for multiple device lines, expanding its distribution beyond the Korean market. The period from 2021 to 2023 saw continued growth in international distribution and industry recognition. Most recently, the company has launched SYNERJET PRO™ and MIGLOU™, both of which have received Korea MFDS approvals in 2026.
Current Operations
HIRONIC's product portfolio today includes SYNERJET PRO™, MIGLOU™, New Doublo™ (marketed in Korea as V-RO LIFTING™), and PICOHI™, covering applications in skin treatment, body contouring, and related aesthetic procedures. The company continues to work with distributors and physicians across its international markets.
In a statement marking the anniversary, HIRONIC said the milestone reflects two decades of work with its distributors, partner physicians, and patients, and that the company intends to continue developing new devices and expanding its international regulatory approvals in the years ahead.
